Volume 5 Supplement 1

Proceedings of the 12-th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Open Access

Elevated serum levels of CXCL13 precede HIV-associated non-Hodgkin’s lymphoma

  • Shehnaz K Hussain1, 2Email author,
  • Daniel Widney3,
  • Lisa Jacobson4,
  • Elizabeth C Breen5,
  • Alexandra Levine6,
  • Roger Detels1,
  • Zuo-Feng Zhang1, 2 and
  • Otoniel Martínez-Maza1, 2, 3, 7, 8
Infectious Agents and Cancer20105(Suppl 1):A24

https://doi.org/10.1186/1750-9378-5-S1-A24

Published: 11 October 2010

Introduction

CXCL13 (BCA-1, BLC), a chemokine constitutively expressed by cells in secondary lymphoid organs, promotes the chemotaxis of B cells to secondary lymphoid organs. There is accumulating evidence that CXCL13 is aberrantly expressed in a variety of lymphomas; thus we sought to define the longitudinal expression pattern of CXCL13 preceding a non-Hodgkin’s lymphoma (NHL) diagnosis in the setting of HIV.

Methods

A nested case-control study was conducted in the setting of two large prospective cohort studies of the natural and treated history of HIV and AIDS, the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS). Archival, pre-cancer diagnosis serum specimens from NHL cases (180 MACS and 30 WIHS) and HIV-seropositive matched controls (180 MACS and 109 WIHS) were assayed for CXCL13 by ELISA. Visit-matched sera from case-control pairs were obtained when available from three time windows preceding NHL diagnosis in the case: 3-5 years pre-NHL (closest to 4 years), 1-3 years pre-NHL (closest to 2 years), and 0-1 year pre-NHL (closest to 0.5 year). These data were analyzed using multivariate conditional logistic regression models to obtain adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for each unit increase in log-transformed CXCL13 for each of the three study visits.

Results

CXCL13 levels were significantly elevated at all three time points preceding the clinical recognition of NHL, 3-5 years: OR=3.66 (95% CI, 2.34-5.74); 1-3 years: OR=6.62 (95% CI, 3.78-11.6); and 0-1 year: OR=3.68 (95% CI, 2.27-5.98). Subgroup analyses revealed that CXCL13 was more strongly associated with systemic NHL compared to central nervous system NHL, and EBV-negative compared to EBV-positive tumors.

Conclusions

These data suggest that CXCL13 may be a biomarker for NHL in the setting of HIV, and is more strongly associated with systemic, EBV-negative tumors. Studies are currently under way to further characterize the role CXCL13, and its receptor CXCR5, in lymphomagenesis.

Declarations

Acknowledgements

This article has been published as part of Infectious Agents and Cancer Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI).The full contents of the supplement are available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.

Authors’ Affiliations

(1)
Department of Epidemiology, University of California
(2)
Jonsson Comprehensive Cancer Center, University of California
(3)
Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA
(4)
Department of Epidemiology, Johns Hopkins University
(5)
Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA
(6)
City of Hope Comprehensive Cancer Center
(7)
Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA
(8)
UCLA AIDS Institute

Copyright

© Hussain et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement